1. Donor-specific cellular immune response against human cardiac valve allografts 
Franciska Hoekstra, MDa, Christiaan Knoop, BSca, Len Vaessen, BSca, Claas Wassenaar, MDb, Nicolet Jutte, PhDa, Egbert Bos, MDc, Ad Bogers, MDc, Willem Weimar, MDa 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 112, Issue 2, Pages (August 1996)
DOI: /S (96)
Copyright © 1996 Mosby, Inc. Terms and Conditions

2. Fig. 1
Donor-specific lympholysis by valve allograft infiltrating cells. Patient 3: lymphocyte cultures derived from the vessel wall. HLA antigens that are matched with valve donor antigens are underlined in the key. LAK, lymphokine-activated killer cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions

3. Fig. 2
Donor-specific lympholysis by valve allograft infiltrating cells. Patient 3: lymphocyte cultures derived from the valve leaflet. HLA antigens that are matched with valve donor antigens are underlined in the key. LAK, lymphokine-activated killer cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions

4. Fig. 3
Donor-specific lympholysis by valve allograft infiltrating cells. Patient 4: lymphocyte cultures derived from the vessel wall. HLA antigens that are matched with valve donor antigens are underlined in the key. LAK, lymphokine-activated killer cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions

5. Fig. 4
Donor-specific lympholysis by valve allograft infiltrating cells. Patient 5: lymphocyte cultures derived from the valve leaflet. HLA antigens that are matched with valve donor antigens are underlined in the key. LAK, lymphokine-activated killer cell.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions